Navigation Links
Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)
Date:12/16/2008

FDA to review Intermezzo(R) (zolpidem tartrate sublingual lozenge) as the first sleep aid specifically designed for the treatment of middle-of-the-night awakenings

PT. RICHMOND, Calif., Dec. 16 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that it has received confirmation from the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for Intermezzo(R) (zolpidem tartrate sublingual lozenge) has been accepted for review by the agency. Intermezzo(R) is a low dose, buffered, sublingual formulation of zolpidem intended to be the first prescription sleep aid indicated for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.

Glenn A. Oclassen, President and Chief Executive Officer of Transcept, commented, "Confirmation that the FDA has accepted the Intermezzo(R) NDA and has begun its review represents another important milestone in our efforts to gain FDA approval for Intermezzo(R), which we believe is positioned to be the first commercially available sleep aid designed specifically for use in the middle of the night when patients awaken and have difficulty returning to sleep. Based on an anticipated standard review process, we currently expect to receive a complete response letter regarding Intermezzo(R) in the fourth quarter of 2009 and to initiate the potential U.S. commercialization and launch in the first half of 2010, if Intermezzo(R) is approved."

The Intermezzo(R) NDA follows the successful completion of two Phase 3 clinical trials. The first Intermezzo(R) Phase 3 trial was a double-blind, placebo-controlled crossover sleep laboratory study of 82 patients, which Transcept believes to be among the largest reported sleep laboratory studies of its type. Results from the study dem
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
2. Transcept Pharmaceuticals Appoints Key Senior Executives
3. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Grade school history lessons often have it that American ... whooping cough, chicken pox, influenza and tuberculosis brought to ... while estimates vary, about 20 million people lived in ... percent of them were killed by European diseases., But ... Arizona State University and Johannes Krause of the University ...
(Date:8/20/2014)... 20, 2014  PAREXEL International Corporation (NASDAQ: ... at the Baird Healthcare Conference in New York.  ... Officer, will be making a presentation on PAREXEL and ... Sept. 3, 2014. A live webcast of ... of PAREXEL,s website at www.PAREXEL.com in the ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient Outcome ... myPROpad™ ePRO tablet with the addition of a touchscreen ... widely used and well-respected Patient Reported Outcome (PRO) instruments ... used during clinical trials and in other health care ... to demonstrate Health-Related Quality of Life outcomes (HRQoL) resulting ...
(Date:8/19/2014)... -- A Geisinger researcher on a personal crusade against ... Disease Control and Prevention (CDC) award recognizing his unprecedented ... Joseph Boscarino , Ph.D. MPH, senior scientist, ... researchers nominated for the Centers for Disease Control and ... Methods and Study Design. "Hepatitis C killed ...
Breaking Biology Technology:Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3PAREXEL International To Present At Baird Healthcare Conference 2EQ-5D™ Assessment Now Available for iPad 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... January 24 The European Commission has granted,marketing ... antidepressant for the treatment of adult patients,with major ... is still great scope for improved therapies to ... from Warneford,Hospital, Oxford, United Kingdom. "Valdoxan is an ...
... has launched www.EyeScience.com to fill a large ... macular degeneration (AMD) in a unique watch-and-learn video format. ... the leading cause of blindness in Americans age 50 ... basic eye anatomy, screening and diagnosis, risk factors, signs ...
... Feb. 24 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, ... Company") (Nasdaq: CSKI ), a,leading ... the People,s Republic of China ("PRC"), today ... Jin Chuang Pharmaceutical Company ("Jin,Chuang"), signed an ...
Cached Biology Technology:Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe 2Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe 3EyeScience Launches Comprehensive Online Resource Devoted to Age-Related Macular Degeneration Education and Prevention 2China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets 2China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets 3
(Date:8/21/2014)... New feeding tube connectors, designed by an international standards ... safety. , According to an invited review published in ... ( NCP ), the official journal of the ... new connectors will greatly reduce the occurrence of misconnection ... , Small-bore connectors, which are used to join medical ...
(Date:8/21/2014)... RUSTON, La. A team of researchers ... innovative method for using affordable, consumer-grade 3D ... implants that can contain antibacterial and chemotherapeutic ... team comprised of doctoral students and research ... nanosystems engineering programs collaborated to create filament ...
(Date:8/21/2014)... An Australian National University (ANU) team has successfully replicated ... way for biological systems powered by sunlight which could ... and so is sunlight. It is an exciting prospect ... cheaply and safely," said Dr Kastoori Hingorani, from the ... ANU Research School of Biology. , Hydrogen offers potential ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Water and sunlight the formula for sustainable fuel 2
... of frozen methane deposits is the likely cause of a ... years ago, according to an international research team led by ... finding is expected to come as a relief to scientists ... might have been touched off by methane melts in the ...
... individuals around the world are alive because of him. ... to make the use of life-saving devices such as ... and heart-lung bypass systems almost commonplace. In the ... biomaterials leader. John Brash, P.Eng., director of the ...
... in preparing for how data from the Sentinel-1 European ... land-cover mapping and crop management. Sentinel-1 is the first ... the GMES initiative. Sentinel-1 is a constellation of ... day and night imagery for use in a range ...
Cached Biology News:Wetlands likely source of methane from ancient warming event 2Wetlands likely source of methane from ancient warming event 3Canadian biomedical engineering pioneer receives international award 2A glimpse of future GMES Sentinel-1 radar images 2
... contains choice of PDMS Stamps (3 PDMS ... 200 micron squares or 100 um x ... mm lines, 3 PDMS nano-patterned stamps with ... and pitch of 400 nm, or 3 ...
...
... The product contains 5 ml of DETACHaBEAD ... release mouse CD4+ T cells from Dynabeads ... mosue CD4+ T cells from Dynabeads Mouse ... cells are suitable for any downstream application ...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Biology Products: